MDCX PRESS-RELEASE SEC Filing Analysis

Latest settled — T+5d

MDCX ▼ -0.33% at T+5d

SHORT call ✓ call won +0.33% · α vs SPY +1.30% · entry $0.3010 → $0.3000

Next anchor: T+20d due 24h ago

Currently $0.3380 · -12.29% from $0.3010 entry (call sign-flipped)

Entry anchored
May 14, 03:59 PM ET
via Databento tick

T+1d

-3.32%

call +3.32% · α +3.26%

$0.2910

settled 29d ago

T+5d

-0.33%

call +0.33% · α +1.30%

$0.3000

settled 23d ago

T+20d

—

call — · α —

—

due 24h ago

T+60d

—

call — · α —

—

in 8w

Price Chart

Loading chart...

Executive Summary

Medicus Pharma reported Q1 2026 results with a net loss of $9.0M (vs. $5.1M a year ago), cash of $6.4M, and disclosed substantial doubt about its ability to continue as a going concern. The company highlighted positive Phase 2 SkinJect data and FDA clearance for Teverelix Phase 2b, but operating expenses rose 69% to $8.6M while revenue remained zero. Post-quarter, it expanded its ATM facility from $15.3M to $50M, signaling ongoing dilution risk.

Key Financial Metrics

EPS

$-0.31

Actionable Insight

The going-concern warning and rapid cash burn (0.7 quarters runway) make this a high-risk name. The expanded $50M ATM facility will likely lead to significant dilution. Traders should watch for further equity raises and any FDA meeting outcomes for SkinJect — positive regulatory news could temporarily offset dilution fears, but the fundamental cash position is precarious.

Key Facts

Net loss widened to $9.0M in Q1 2026 from $5.1M in Q1 2025
Operating expenses increased 69% to $8.6M (R&D $2.7M, G&A $5.9M)
Cash and equivalents stood at $6.4M as of March 31, 2026
Substantial doubt exists regarding ability to continue as a going concern
ATM facility expanded post-quarter from ~$15.3M to $50M
Raised ~$10M in gross proceeds from ATM and SEPA during Q1
No revenue reported; clinical-stage company with no approved products
Positive Phase 2 SkinJect data and FDA clearance for Teverelix Phase 2b noted
LifeArc royalty rate reduced from ~4% to 2% on Teverelix net sales

Financial Impact

Net loss of $9.0M vs $5.1M YoY; cash burn rate ~$8.6M/quarter; $6.4M cash on hand implies ~0.7 quarters of runway without additional financing

net lossoperating expensescash positiondilution

Risk Factors

Going-concern risk — only $6.4M cash vs $8.6M quarterly burn
Massive dilution from expanded $50M ATM facility
No approved products or revenue; all programs are clinical-stage
Historical performance shows 0% win rate at T+20 on prior reports, with average -28% return
Net loss widening 76% YoY signals accelerating cash burn

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Analyst Consensus

90% bullish (10 analysts)

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3295423

7 reports for MDCX

T+1T+5T+20T+60

60% Hit rate 3 of 5 directional calls best @ T+20▲ +7.51%May 6, 2026

Filters

Reports for MDCX — sortable, filterable
	Type				Now
May 14, 2026 29d ago	Press Release BEARISH ★ 6/10	$0.3010 $0.3000	▲ +0.33%	▲ +1.30%	$0.3380 (−12.29%)
May 6, 2026 5w ago	Press Release BULLISH ★ 7/10	$0.3330 $0.3150	▼ −5.41%	▼ −6.54%	$0.3380 (+1.50%)
Apr 6, 2026 9w ago	Press Release NEUTRAL ★ 4/10	$0.4910 $0.4020	▼ −18.13%	▼ −22.26%	$0.3380 (−31.16%)
Apr 1, 2026 10w ago	Press Release BULLISH ★ 7/10	$0.4200 $0.4420	▲ +5.24%	▲ +1.47%	$0.3380 (−19.52%)
Mar 16, 2026 12w ago	Press Release BULLISH ★ 8/10	$0.5240 $0.5000	▼ −4.58%	▼ −2.54%	$0.3380 (−35.50%)
Mar 9, 2026 13w ago	Press Release BULLISH ★ 8/10	$0.5200 $0.5240	▲ +0.77%	▲ +2.12%	$0.3380 (−35.00%)
Mar 5, 2026 14w ago	Press Release BULLISH ★ 8/10	$0.6780 $0.5000	▼ −26.25%	▼ −24.02%	$0.3380 (−50.15%)

US Market Status

Market Closed — Opens Mon (49h 43m)

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access